Tech Company Financing Transactions
Aqemia Funding Round
Wendel Group, Bpifrance and Elaia Partners invested in a $32.5 million Series A capital raise for Aqemia. The round closed on 1/30/2024.
Transaction Overview
Company Name
Announced On
1/30/2024
Transaction Type
Venture Equity
Amount
$32,470,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the growth of its wholly-owned pipeline of drug discovery projects and assets, as well as further scale its proprietary GenAI and physics drug discovery platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Boulevard Pasteur
Paris, 75015
France
Paris, 75015
France
Phone
Undisclosed
Website
Email Address
Overview
Aqemia is a next-generation pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to scale the drug discovery process, by leveraging a unique-in-the world technology combining quantum-inspired physics and machine learning.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Maximilien Levesque
Chief Operating Officer
Emmanuelle Martiano
Browse more venture capital transactions:
Prev: 1/30/2024: Tau venture capital transaction
Next: 1/30/2024: Spark Advisors venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs